Efficacy of IV iron compared to oral iron for increment of haemoglobin level in anemic chronic kidney disease patients on erythropoietin therapy

Journal of the Nepal Medical Association

Volumn 51, Issue 3, 2011, Pages 133-136

  Adhikary, L ^a   Acharya, S ^a  

^a KATHMANDU MEDICAL COLLEGE TEACHING HOSPITAL   (Nepal)

Author keywords

Anemia; Chronic kidney disease; Iron

Indexed keywords

FERRIC HYDROXIDE SUCROSE; FERRITIN; FERROUS FUMARATE; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOTENSION; IRON DEFICIENCY ANEMIA; IRON THERAPY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TRANSFERRIN BLOOD LEVEL;

ADMINISTRATION, ORAL; ADULT; ANEMIA; CHRONIC DISEASE; ERYTHROPOIETIN; FEMALE; FERRIC COMPOUNDS; FERROUS COMPOUNDS; GLUCARIC ACID; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TRANSFERRIN;

EID: 84861852784     PISSN: 00282715     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Seiler S. Anemia of chronic renal failure: new treatment alternative. CANNT J. 2000;10(3):35-39.
2. Silverberg DS, Iaina A, Peer G, Kaplan E, Levi BA, Frank N, et al. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis. 1996;27(2):234-238.
3. Collins AJ, Kasiske B, Herzog C. Excerpts from the United States renal data system 2004 annual data report: atlas of endstage renal disease in the United States. Am J Kidney Dis. 2005;45:S8-S270.
4. Macdougall IC. Strategies for iron supplementation: oral versus intravenous. Kidney Int Suppl. 1999;69:S61-S66.
5. Hudson JQ, Comstock TJ. Considerations for optimal iron use for anemia due to chronic kidney disease. Clin Ther. 2001;23(10):1637-1671.
6. Szczech LA, Barnhart HX, Inrig JK. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008;74:791-798.
7. Aggarwal HK, Nand N, Singh S. Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin. J Assoc Physicians India. 2003;51:170-174.
8. Besarab A, Amin N, Ahsan M. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol. 2000;11:530-538.
9. DeVita MV, Frumkin D, Mittal S. Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients. Clin Nephrol. 2003;60:335-340.
10. Macdougall IC, Tucker B, Thompson J. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int. 1996;50:1694-1699.
11. Taylor JE, Peat N, Porter C. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant. 1996;11:1079-1083.
12. Sunder-Plassmann G, Hörl WH. Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant. 1995;10:2070-2076.
13. Qunibi WY, Martinez C, Smith M. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron defi ciency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant. 2011;26(5):1599-1607.
14. Van Wyck DB, Roppolo M, Martinez C. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int. 2005;68:2846-2856.
15. Stoves J, Inglis H, Newstead CG. A randomized study of oral vs. intravenous iron supplementation in patients with progressive renal insuffi ciency treated with erythropoietin. Nephrol Dial Transplant. 2001;16:967-974.
16. Charytan C, Qunibi W, Bailie GR. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract. 2005;100:c55-c62.
17. National Kidney Foundation. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis. 2001;37:S182-S238.
18. Agarwal R, Rizkala AR, Bastani B. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol 2006;26:445-454.
19. Clinical Practice Guidelines for Chronic Kidney Disease. Association of level of GFR with indices of functioning and well-being. Available from: http://www.kidney.org/Professionals/Kdoqi/guidelines_ckd/p6_comp_g12.htm
20. Spinowitz BS, Kausz AT, Baptista J. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol. 2008;19:1599-1605.
21. Basarab A, Coyne DW. Iron supplementation to treat anemia in patients with chronic kidney disease. Natural reviews Nephrology. 2010;6:699-710.